Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2022

Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2022

  • January 2022 •
  • 100 pages •
  • Report ID: 6133958 •
  • Format: PDF
“Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Ionotropic Glutamate Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Ionotropic Glutamate Receptor Antagonists Understanding

Ionotropic Glutamate Receptor Antagonists: Overview
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS) and exerts its biological activity through a variety of receptors. Glutamate receptors (GluRs) are divided into two major classes on the basis of the mechanism by which they relay their signal: the ionotropic glutamate receptors (iGluRs), which are ligand-gated cation channels, and the metabotropic glutamate receptors (mGluRs) that are G protein-coupled receptors. It is widely accepted that glutamate-mediated neuronal hyperexcitation plays a causative role in eliciting seizures. Among glutamate receptors, the roles of N-methyl-D-aspartate (NMDA) and ?-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors in physiological and pathological conditions represent major clinical research targets. NMDA or AMPA receptor antagonists have been shown to inhibit seizures in animal models, suggesting a potential role for NMDA and AMPA receptor antagonists in anti-seizure drug development.
"Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ionotropic Glutamate Receptor Antagonists pipeline landscape is provided which includes the disease overview and Ionotropic Glutamate Receptor Antagonists treatment guidelines. The assessment part of the report embraces, in depth Ionotropic Glutamate Receptor Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ionotropic Glutamate Receptor Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Ionotropic Glutamate Receptor Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Ionotropic Glutamate Receptor Antagonists.

Ionotropic Glutamate Receptor Antagonists Emerging Drugs Chapters
This segment of the Ionotropic Glutamate Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ionotropic Glutamate Receptor Antagonists Emerging Drugs
• AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor. In April 2021, Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-05 for the treatment of major depressive disorder (MDD), and has granted the application Priority Review.
• REL-1017: Relmada Therapeutics
REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with major depressive disorder (MDD), has entered its Phase III registration program as an adjunctive treatment for MDD. Data from the Phase II trial with REL-1017 suggest rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo on efficacy measures. Safety and tolerability results in the Phase II study were also consistent with those reported in previously reported Phase I studies. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD.
Further product details are provided in the report……..

Ionotropic Glutamate Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Ionotropic Glutamate Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Ionotropic Glutamate Receptor Antagonists
There are approx. 30+ key companies which are developing the therapies for Ionotropic Glutamate Receptor Antagonists. The companies which have their Ionotropic Glutamate Receptor Antagonists drug candidates in the most advanced stage, i.e. Pre-registration include, Axsome Therapeutics.
• Phases
This report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Ionotropic Glutamate Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ionotropic Glutamate Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ionotropic Glutamate Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ionotropic Glutamate Receptor Antagonists drugs.

Ionotropic Glutamate Receptor Antagonists Report Insights
• Ionotropic Glutamate Receptor Antagonists Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ionotropic Glutamate Receptor Antagonists Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Ionotropic Glutamate Receptor Antagonists drugs?
• How many Ionotropic Glutamate Receptor Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ionotropic Glutamate Receptor Antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ionotropic Glutamate Receptor Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ionotropic Glutamate Receptor Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Axsome Therapeutics
• Seelos Therapeutics
• Relmada Therapeutics
• Algernon Pharmaceuticals
• Biohaven Pharmaceuticals
• Otsuka Pharmaceutical
• Otonomy

Key Products
• AXS-05
• SLS-002
• REL-1017
• Ifenprodil
• BHV-5000
• AVP-786
• OTO-313